Sware

Sware is a life sciences software company whose Res_Q platform and broader GxP Suite automate the validation work required by regulators such as the FDA for computerized systems used in drug and device development and manufacturing. Res_Q is a cloud-based, open-API system of record that consolidates validation processes for IT, manufacturing and laboratory systems, using risk assessments to trigger workflows and allocate work according to risk profile. The company frames the problem it addresses as "validation debt" — the accumulating unpaid cost of release, testing, GxP and business requirements that grows each time a life sciences organization adopts new technology or a vendor ships an update.

The GxP Suite spans software validation, plant and equipment validation (equipment records, calibration tracking and change management), medical device and Software as a Medical Device including continuous compliance for AI/ML, an "AI for GxP" offering, and GxPNext, which embeds agentic validation into software development pipelines. Sware describes the suite as built on the Res_Q Data Cloud, a curated body of validation knowledge assembled over roughly a decade, and markets AI agents that automate validation tasks while keeping decisions explainable, traceable and reversible. Company-published figures cite up to 80% faster validation time, 60% lower lifetime CSV costs and more than 30 industry application integrations.

Alongside the platform, Sware provides professional services and validation deliverables, positioning itself as a supplier of both software and skilled validation resources. Published case studies cover a global gene therapy CDMO, a global biologics CDMO, biopharmaceutical, biotechnology, pharmaceutical research and molecular medicine companies, and it publishes whitepapers on topics including FDA CSA, GAMP 5, ERP validation and agentic AI compliance.

Founding story

Sware was founded by validation veterans with prior careers in pharmaceutical compliance who rejected the trade-off they saw customers making between speed and quality, innovation and validation, and progress and paperwork. Bryan Ennis is identified as a co-founder and serves as Chief Quality Officer.

Business model

Sware sells a subscription SaaS validation platform (Res_Q / the GxP Suite) to regulated life sciences organizations, complemented by professional services that deliver validation work and implementation support. The company positions the SaaS model as adapting to regulatory and industry shifts continuously, avoiding repeated short-term vendor cycles.

Recurring software revenue from the Res_Q SaaS platform, supplemented by validation professional services engagements.

Traction

Sware reports more than 30 application integrations and publishes customer case studies with named and anonymized life sciences organizations, including a global gene therapy CDMO, a global biologics CDMO, a biopharmaceutical company, a biotechnology company, a pharmaceutical research company and a molecular medicine company; one case study cites over $130,000 in annual savings, another a 30-40% reduction in validation time and another a 75% acceleration in validation time. Referenced customers and users include G1 Therapeutics and Nuvolo, and Salesforce leadership has publicly endorsed Res_Q's integration with Salesforce Life Sciences Cloud. Total capital raised since inception was $26 million as of June 2024.

Latest developments

Recent activity includes the announced partnership with ZenQMS to simplify GxP validation across the software lifecycle, selection as Box's 2025 Life Sciences Partner of the Year, launch of the AI-driven Sware GxP Suite with agentic validation and the GxPNext developer offering, and publication of whitepapers on validating AI in GxP and managing the compliance of agentic AI.